The trend toward larger deal sizes is likely to continue as companies seek to bolster their pipelines amid a looming patent ...

What are biopharma VCs looking to invest in this year? Autoimmune disorders, osteoporosis, and cardiovascular disease are ...

JP Morgan CEO Jamie Dimon said businesses are "encouraged by expectations for a more pro-growth agenda" heading into 2025.

According to JP Morgan analysts, if the SEC approves crypto ETFs, both XRP and Solana could attract up to $14bn in ...

The radiopharmaceutical developer expanded its reach, acquiring R&D, isotope production, manufacturing, and distribution.

JP Morgan’s James Sullivan says that China's muted growth outlook should not bar investors from wading into the markets there ...

JP Morgan and UBS have topped the charts for mergers and acquisitions (M&A) financial advisers in the Asia-Pacific region for ...

JPMorgan’s net income soared 50% to more than $14 billion in the fourth quarter as the bank’s profit and revenue easily beat ...

Potential antitrust deregulation could foster a more favourable environment for larger M&A deals in 2025, though skepticism ...

The JP Morgan Healthcare Conference will show us many examples of how AI is affecting Healthcare. Cerebras and Nvidia are ...